Beyfortus is a single-dose injection that protects babies against respiratory syncytial virus, commonly known as RSV. Unlike a traditional vaccine, it doesn’t teach the immune system to make its own antibodies. Instead, it delivers ready-made antibodies directly into the baby’s body, providing immediate protection that lasts at least five months.
How Beyfortus Works
Beyfortus contains a lab-made antibody called nirsevimab. When injected into a baby’s thigh muscle, these antibodies circulate in the bloodstream and latch onto the RSV virus before it can infect cells in the lungs. This is called passive immunity: the baby receives pre-built protection rather than generating its own. Because the antibodies are long-lasting by design, a single shot covers an entire RSV season.
This is a meaningful distinction from traditional vaccines. A flu shot, for example, prompts your immune system to produce its own defenses over a week or two. Beyfortus skips that step entirely, which is important for newborns and young infants whose immune systems are still too immature to mount a strong response on their own.
How Well It Works
In the two pivotal clinical trials submitted to the FDA, Beyfortus reduced medically attended RSV lower respiratory tract infections by 70% to 75% compared to placebo over the 150 days after injection. Among smaller infants who weighed under 5 kg (about 11 pounds) at baseline and received the recommended dose, efficacy climbed to 86%. These numbers reflect real-world outcomes: fewer doctor visits, fewer ER trips, and fewer hospitalizations for RSV-related breathing problems in the babies who received the shot.
Which Babies Should Get It
The CDC recommends Beyfortus for infants younger than 8 months who are born during or entering their first RSV season, which typically runs from fall through spring. The shot is specifically recommended when:
- The mother did not receive an RSV vaccine during pregnancy
- The mother’s RSV vaccination status is unknown
- The infant was born within 14 days of the mother’s RSV vaccination (not enough time for protective antibodies to transfer)
If the mother received an RSV vaccine more than 14 days before delivery, her antibodies have already crossed the placenta, and the baby typically doesn’t need Beyfortus for that first season.
Older Babies at Higher Risk
A smaller group of children between 8 and 19 months old qualifies for Beyfortus heading into their second RSV season. These are children facing elevated risk of severe illness, including those with chronic lung disease from premature birth (who needed oxygen, steroids, or diuretics in the six months before RSV season), children with severe immune deficiency, children with cystic fibrosis who have significant lung complications or low weight for their length, and American Indian or Alaska Native children.
Dosing by Weight and Age
Beyfortus is given as an intramuscular injection, typically in the thigh. The dose depends on the baby’s weight and age at the time of the shot:
- Under 5 kg (under 11 lbs): 50 mg, one injection
- 5 kg or more (11 lbs and up): 100 mg, one injection
- Ages 8 to 19 months (second-season group): 200 mg, given as two 100 mg injections at the same visit
For most babies, that single shot before or at the start of RSV season is all that’s needed. There is no monthly follow-up dose.
How Beyfortus Differs From Synagis
Before Beyfortus, the only antibody product available for RSV prevention was palivizumab (brand name Synagis). Synagis required monthly injections throughout RSV season, typically five doses over five months, and was only approved for high-risk premature infants and children with certain heart or lung conditions. Most healthy babies didn’t qualify.
Beyfortus changed both of those limitations. Its engineered antibody was designed to stay active in the body longer, so one dose provides at least five months of protection. And it’s recommended broadly for all infants entering their first RSV season who haven’t already received maternal antibody protection, not just those born prematurely.
Side Effects
The most commonly reported side effect in clinical trials was a mild reaction at the injection site: redness, swelling, or tenderness in the thigh where the shot was given. These reactions are typical of any intramuscular injection in infants and generally resolve within a day or two. Rash and fever were also reported at low rates.
Beyfortus is contraindicated only for infants who have had a severe allergic reaction (such as anaphylaxis) to any component of the product. For the vast majority of babies, it is well tolerated.
Cost and Coverage
Beyfortus is included in the CDC’s recommended pediatric immunization schedule, which means it falls under the Vaccines for Children (VFC) program. Through VFC, the injection is available at no cost to children who are Medicaid-eligible, uninsured, underinsured, or American Indian or Alaska Native. Underinsured children can receive VFC-covered immunizations at federally qualified health centers and rural health clinics. Birthing hospitals can also serve as VFC providers and administer Beyfortus before a newborn goes home.
Most private insurance plans are required to cover immunizations recommended by the Advisory Committee on Immunization Practices without charging a copay, though coverage details vary by plan. If you’re unsure whether your child is covered, your pediatrician’s office can typically verify eligibility before the appointment.
When to Get It
Timing matters. RSV season in most of the continental United States peaks between late fall and early spring. The CDC suggests administering Beyfortus shortly before or early in the season so that antibody levels are highest when the virus is circulating most heavily. For babies born during RSV season, the shot can be given before hospital discharge or at an early well-child visit. For babies born in the spring or summer who will enter their first RSV season in the fall, the shot is typically given in October or November.
Because protection lasts at least five months from the injection date, getting the timing right ensures coverage through the peak months when your baby is most likely to encounter the virus.